nsaids modulate cdkn2a, tp53, and dna content risk for progression to esophageal adenocarcinoma非甾体抗炎药调节cdkn2a tp53,dna可能发展为食管腺癌的内容.pdfVIP

PLoS MEDICINE NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal Adenocarcinoma 1,2[* 2[ 1,2,3 4 1,2 5 Patricia C. Galipeau , Xiaohong Li , Patricia L. Blount , Carlo C. Maley , Carissa A. Sanchez , Robert D. Odze , Kamran Ayub6, Peter S. Rabinovitch1,2,7, Thomas L. Vaughan2,8, Brian J. Reid1,2,3,9 1 Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, 2 Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, 3 Department of Medicine, University of Washington, Seattle, Washington, United States of America, 4 Cellular and Molecular Oncogenesis Program, Wistar Institute, Philadelphia, Pennsylvania, United States of America, 5 Department of Pathology, Harvard Medical School and Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 6 Department of Gastroenterology, Virginia Mason Medical Center, Seattle, Washington, United States of America, 7 Department of Pathology, University of Washington, Seattle, Washington, United States of America, 8 Department of Epidemiology, University of Washington, Seattle, Washington, United States of America, 9 Genome Sciences, University of Washington, Seattle, Washington, United States of America Funding: This study was funded by A B S T R A C T the US National Institutes of Health (P01 CA91955, R01 CA61202, and R01 CA78828) with interim support from the Fred Hutchinson Cancer Background Research Center. The funders had no role in study design, data collection S